Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.

  title={Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.},
  author={Mickey K Kim and Takuya Osada and William T. Barry and Xiao Yi Yang and Jennifer A. Freedman and Katherine A. Tsamis and Michael B. Datto and Bryan M. Clary and Timothy M. Clay and Michael Andew Morse and Philip G Febbo and H Kim Lyerly and David S Hsu},
  journal={Molecular cancer therapeutics},
  volume={11 7},
Despite advances in contemporary chemotherapeutic strategies, long-term survival still remains elusive for patients with metastatic colorectal cancer. A better understanding of the molecular markers of drug sensitivity to match therapy with patient is needed to improve clinical outcomes. In this study, we used in vitro drug sensitivity data from the NCI-60 cell lines together with their Affymetrix microarray data to develop a gene expression signature to predict sensitivity to oxaliplatin. To… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 40 references

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized on July 6, 2017

  • C Tournigand, T Andre, E Achille, G Lledo, M Flesh, D Mery-Mignard
  • Author Manuscript Published OnlineFirst on…
  • 2012
2 Excerpts

National Cancer Institute (Genomics and Bioinformatics Group) [updated

  • Jan 12,
  • 2012
1 Excerpt

National Cancer Institute (Developmental Therapeutics Program) [updated Nov 2, 2011].available from

  • 2011
1 Excerpt

Resistance of colon cancer cells to 5-FU or oxaliplatin enriches for tumor stem cells

  • NA Dallas, L. Xia, F. Fan
  • Gastrointestinal Cancer Symposium
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…